中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
2期
177-179
,共3页
林海洋%薛诚%毛小洁%陈恩福%饶高峰%吴金友
林海洋%薛誠%毛小潔%陳恩福%饒高峰%吳金友
림해양%설성%모소길%진은복%요고봉%오금우
糖尿病,2型%甘精胰岛素%瑞格列奈
糖尿病,2型%甘精胰島素%瑞格列奈
당뇨병,2형%감정이도소%서격렬내
Diabetes,type 2%Insulin glargine%Novonorm
目的 观察甘精胰岛素联合瑞格列奈治疗初诊2型糖尿病的临床疗效.方法 选择初诊2型糖尿病患者112例随机分为两组,观察组56例采用甘精胰岛素联合瑞格列奈治疗,对照组采用诺和灵30 R进行治疗,比较治疗前后两组空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)水平变化,及血糖达标时间、胰岛素用量及低血糖发生率情况.结果 两组治疗后FPG、2 hPG及HbA1c水平均明显降低(均P<0.05),但两组治疗后FPG、2 hPG及HbA1c水平差异无均统计学意义(均P>0.05).观察组血糖达标时间、胰岛素用量及低血糖发生率均少于对照组(均P<0.05).结论 甘精胰岛素联合瑞格列奈治疗初诊2型糖尿病,能有效的控制空腹和饭后血糖,且血糖达标时间短,胰岛素用量少,大大降低了低血糖的发生.
目的 觀察甘精胰島素聯閤瑞格列奈治療初診2型糖尿病的臨床療效.方法 選擇初診2型糖尿病患者112例隨機分為兩組,觀察組56例採用甘精胰島素聯閤瑞格列奈治療,對照組採用諾和靈30 R進行治療,比較治療前後兩組空腹血糖(FBG)、餐後2 h血糖(2 hPG)、糖化血紅蛋白(HbA1c)水平變化,及血糖達標時間、胰島素用量及低血糖髮生率情況.結果 兩組治療後FPG、2 hPG及HbA1c水平均明顯降低(均P<0.05),但兩組治療後FPG、2 hPG及HbA1c水平差異無均統計學意義(均P>0.05).觀察組血糖達標時間、胰島素用量及低血糖髮生率均少于對照組(均P<0.05).結論 甘精胰島素聯閤瑞格列奈治療初診2型糖尿病,能有效的控製空腹和飯後血糖,且血糖達標時間短,胰島素用量少,大大降低瞭低血糖的髮生.
목적 관찰감정이도소연합서격렬내치료초진2형당뇨병적림상료효.방법 선택초진2형당뇨병환자112례수궤분위량조,관찰조56례채용감정이도소연합서격렬내치료,대조조채용낙화령30 R진행치료,비교치료전후량조공복혈당(FBG)、찬후2 h혈당(2 hPG)、당화혈홍단백(HbA1c)수평변화,급혈당체표시간、이도소용량급저혈당발생솔정황.결과 량조치료후FPG、2 hPG급HbA1c수평균명현강저(균P<0.05),단량조치료후FPG、2 hPG급HbA1c수평차이무균통계학의의(균P>0.05).관찰조혈당체표시간、이도소용량급저혈당발생솔균소우대조조(균P<0.05).결론 감정이도소연합서격렬내치료초진2형당뇨병,능유효적공제공복화반후혈당,차혈당체표시간단,이도소용량소,대대강저료저혈당적발생.
Objective To observe the clinical effects of insulin glargine combined with novonorm in treatment of patients with newly diagnosed type 2 diabetes. Methods 112 cases of newly diagnosed type 2 diabetes patients were randomly separated into observation group(56 cases)and control group(56 cases). Observation group was treated with insulin glargine combined with novonorm. Control group was treated with novolin30R. The levels of FPG,2hPG and HbA1c before and after treatment,the control time of blood sugar,amounts of insulin and incidence of low blood sugar were observed in both groups. Results Compared with pre-treatment, FPG,2hPG and HbA1 c were significantly decreased (all P <0.05) after treatment, but there were no significant differences in both two groups (P >0. 05). The control time of blood sugar, amounts of insulin and incidence of low blood sugar in observation group were significantly lower than those in control group (all P < 0.05). Conclusion Insulin glargine combined with novonorm in treatment of patients with newly diagnosed type 2 diabetes could effectively control blood sugar,shorten the control time of blood sugar,decrease amounts of insulin,and low incidence of low blood sugar.